Acutus Medical completed a $170 million financing, including a $100 million Series D equity financing and a $70 million credit facility.
The funding is intended to accelerate commercialization and facilitate global business development activities as the company continues to transform arrhythmia care through distinct, innovative technologies designed to provide physicians and patients with improved results.
The credit facility was provided by OrbiMed Credit and Royalties Fund and Deerfield Management.
Acutus provides next-generation electrophysiology technology solutions that can enable personalized and adaptive approaches to therapy.
